Scarica l'app Stockscreener
9.34
0.41%
-0.06
Precedente Chiudi:
$9.40
Aprire:
$9.34
Volume 24 ore:
99,824
Relative Volume:
0.59
Capitalizzazione di mercato:
$308.98M
Reddito:
$65.42M
Utile/perdita netta:
$-32.96M
Rapporto P/E:
-7.3543
EPS:
-1.27
Flusso di cassa netto:
$-19.87M
1 W Prestazione:
-11.85%
1M Prestazione:
-14.27%
6M Prestazione:
-21.86%
1 anno Prestazione:
+46.96%
Intervallo 1D:
$9.23
$9.555
Intervallo di 1 settimana:
$9.22
$10.80
Portata 52W:
$6.27
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Nome
Neuropace Inc
Settore
Industria
Telefono
(650) 237-2700
Indirizzo
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Confronta NPCE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
9.34 | 310.97M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
125.28 | 215.34B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.52 | 146.15B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
362.54 | 136.97B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.12 | 115.69B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
84.13 | 48.77B | 5.88B | 1.34B | 577.90M | 2.3455 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-03-14 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Iniziato | Leerink Partners | Outperform |
| 2023-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Iniziato | Lake Street | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Iniziato | Robert W. Baird | Outperform |
| 2021-05-17 | Iniziato | JP Morgan | Overweight |
| 2021-05-17 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Neuropace Inc Borsa (NPCE) Ultime notizie
What technical models suggest about NeuroPace Inc.’s comeback2025 Big Picture & High Return Trade Opportunity Guides - newser.com
Published on: 2025-11-04 02:38:39 - newser.com
Evaluating NeuroPace Inc. with trendline analysisTrade Analysis Summary & Weekly Market Pulse Updates - newser.com
Real time alert setup for NeuroPace Inc. performance2025 Institutional Moves & Weekly Setup with High ROI Potential - newser.com
Using RSI to spot recovery in NeuroPace Inc.Bull Run & Low Drawdown Investment Ideas - newser.com
Why NeuroPace Inc. stock is a value investor pickSwing Trade & Safe Investment Capital Preservation Plans - newser.com
Will NeuroPace Inc. stock gain from government policies2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - newser.com
How to escape a deep drawdown in NeuroPace Inc.Earnings Recap Summary & Daily Stock Momentum Reports - newser.com
NeuroPace Inc (NPCE) Q3 2025 Earnings Report Preview: What to Look For - Yahoo Finance
Can momentum traders help lift NeuroPace Inc.Trade Volume Summary & Advanced Technical Analysis Signals - newser.com
Using data tools to time your NeuroPace Inc. exitJuly 2025 Final Week & Real-Time Stock Price Movement Reports - newser.com
What technical signals suggest for NeuroPace Inc. stockMarket Sentiment Report & AI Based Trade Execution Alerts - newser.com
What is the fair value of NeuroPace Inc. stock now2025 Short Interest & Comprehensive Market Scan Insights - newser.com
Will NeuroPace Inc. price bounce be sustainableMarket Risk Report & AI Enhanced Execution Alerts - newser.com
Why NeuroPace Inc. stock is seen as undervaluedWeekly Investment Summary & Fast Exit and Entry Trade Guides - newser.com
Can NeuroPace Inc. stock sustain revenue growthJuly 2025 Gainers & Weekly Sector Rotation Insights - newser.com
Will NeuroPace Inc. stock recover faster than marketJuly 2025 Recap & Expert Approved Momentum Trade Ideas - newser.com
Tools to assess NeuroPace Inc.’s risk profilePortfolio Performance Report & Consistent Profit Focused Trading Strategies - newser.com
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Operating expenses (excl. COGS) of Neuropace, Inc. – BOATS:NPCE - TradingView
Can NeuroPace Inc. stock resist market sell offsTrade Volume Summary & AI Enhanced Trading Alerts - newser.com
NeuroPace Inc. stock outlook for YEARTrade Volume Summary & High Win Rate Trade Alerts - newser.com
Can NeuroPace Inc. stock withstand economic slowdown2025 Valuation Update & High Yield Stock Recommendations - newser.com
Applying Elliott Wave Theory to NeuroPace Inc.Market Trend Summary & Consistent Profit Trade Alerts - newser.com
Does NeuroPace Inc. fit your quant trading modelJuly 2025 Institutional & Real-Time Stock Movement Alerts - newser.com
Neuropace Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Neuropace, Inc. (NPCE) Stock forecasts - Yahoo! Finance UK
Strategies to average down on NeuroPace Inc.Portfolio Profit Report & Smart Allocation Stock Tips - newser.com
Neuropace Inc Azioni (NPCE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neuropace Inc Azioni (NPCE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
0.78%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):